



Slc39a14 Cas9-CKO Strategy

Designer: Shilei Zhu

Project Overview

Project Name***Slc39a14***


Project type**Cas9-CKO**

Strain background**C57BL/6JGpt**

Conditional Knockout strategy



This model will use CRISPR/Cas9 technology to edit the *Slc39a14* gene. The schematic diagram is as follows:



Technical routes

- The *Slc39a14* gene has 13 transcripts. According to the structure of *Slc39a14* gene, exon3-exon5 of *Slc39a14-202* (ENSMUST00000068044.13) transcript is recommended as the knockout region. The region contains start codon ATG. Knock out the region will result in disruption of protein function.
- In this project we use CRISPR/Cas9 technology to modify *Slc39a14* gene. The brief process is as follows:CRISPR/Cas9 system and Donor were microinjected into the fertilized eggs of C57BL/6JGpt mice. Fertilized eggs were transplanted to obtain positive F0 mice which were confirmed by PCR and sequencing. A stable F1 generation mouse model was obtained by mating positive F0 generation mice with C57BL/6JGpt mice.
- The flox mice will be knocked out after mating with mice expressing Cre recombinase, resulting in the loss of function of the target gene in specific tissues and cell types.



集萃药康
GemPharmatech

Notice

- According to the existing MGI data, Homozygotes for a null allele show dwarfism, scoliosis, osteopenia, short long bones, altered gluconeogenesis and chondrocyte differentiation, low plasma IGF-I and liver zinc levels. Homozygotes for another null allele show reduced liver zinc levels and hepatocyte proliferation after hepatectomy.
- The *Slc39a14* gene is located on the Chr14. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.
- This Strategy is designed based on genetic information in existing databases. Due to the complexity of biological processes, all risk of loxp insertion on gene transcription, RNA splicing and protein translation cannot be predicted at existing technological level.



Gene information (NCBI)

Slc39a14 solute carrier family 39 (zinc transporter), member 14 [Mus musculus (house mouse)]

Gene ID: 213053, updated on 31-Jan-2019

Summary



Official Symbol Slc39a14 provided by [MGI](#)

Official Full Name solute carrier family 39 (zinc transporter), member 14 provided by [MGI](#)

Primary source [MGI:MGI:2384851](#)

See related [Ensembl:ENSMUSG00000022094](#)

Gene type protein coding

RefSeq status VALIDATED

Organism [Mus musculus](#)

Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus

Also known as FAD-123, ZIP-14, Zip14, fad123

Expression Ubiquitous expression in liver adult (RPKM 12.6), liver E18 (RPKM 11.1) and 28 other tissues [See more](#)


Orthologs [human](#) [all](#)

Transcript information (Ensembl)

The gene has 13 transcripts, all transcripts are shown below:

| Name | Transcript ID | bp | Protein | Biotype | CCDS | UniProt | Flags |
|--------------|---------------------------------------|------|-----------------------|-----------------|---------------------------|----------------------------|---------------------------------|
| Slc39a14-202 | ENSMUST00000068044.13 | 4926 | 489aa | Protein coding | CCDS36969 | Q75N73 | TSL:5 GENCODE basic APPRIS P3 |
| Slc39a14-201 | ENSMUST00000022688.9 | 2098 | 489aa | Protein coding | CCDS49536 | A0A0R4J1V1 | TSL:1 GENCODE basic APPRIS ALT2 |
| Slc39a14-210 | ENSMUST00000152067.7 | 2075 | 489aa | Protein coding | CCDS49536 | A0A0R4J1V1 | TSL:1 GENCODE basic APPRIS ALT2 |
| Slc39a14-212 | ENSMUST00000152442.7 | 734 | 164aa | Protein coding | - | D3Z6P5 | CDS 3' incomplete TSL:5 |
| Slc39a14-209 | ENSMUST00000151011.7 | 508 | 129aa | Protein coding | - | D3YXD7 | CDS 3' incomplete TSL:2 |
| Slc39a14-203 | ENSMUST00000127000.1 | 479 | 109aa | Protein coding | - | D3Z354 | CDS 3' incomplete TSL:5 |
| Slc39a14-204 | ENSMUST00000139284.1 | 458 | 64aa | Protein coding | - | D3Z4Q7 | CDS 3' incomplete TSL:2 |
| Slc39a14-206 | ENSMUST00000143153.1 | 374 | 48aa | Protein coding | - | D3Z3C5 | CDS 3' incomplete TSL:5 |
| Slc39a14-208 | ENSMUST00000146453.1 | 5117 | No protein | Retained intron | - | - | TSL:2 |
| Slc39a14-211 | ENSMUST00000152202.7 | 1398 | No protein | Retained intron | - | - | TSL:2 |
| Slc39a14-213 | ENSMUST00000155825.1 | 845 | No protein | Retained intron | - | - | TSL:3 |
| Slc39a14-205 | ENSMUST00000142598.1 | 436 | No protein | Retained intron | - | - | TSL:2 |
| Slc39a14-207 | ENSMUST00000145040.1 | 364 | No protein | Retained intron | - | - | TSL:5 |


The strategy is based on the design of *Slc39a14-202* transcript, The transcription is shown below





集萃药康
GemPharmatech


Genomic location distribution



Protein domain



Mouse phenotype description(MGI)



Phenotypes affected by the gene are marked in blue. Data quoted from MGI database(<http://www.informatics.jax.org/>).

According to the existing MGI data, Homozygotes for a null allele show dwarfism, scoliosis, osteopenia, short long bones, altered gluconeogenesis and chondrocyte differentiation, low plasma IGF-I and liver zinc levels. Homozygotes for another null allele show reduced liver zinc levels and hepatocyte proliferation after hepatectomy.



If you have any questions, you are welcome to inquire.

Tel: 400-9660890



集萃药康生物科技
GemPharmatech Co.,Ltd

